Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S. 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
Winter Storm Disrupts Northeast Travel as Snow and Ice Blanket New York, New Jersey 
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025 
Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
NEW ORLEANS, Nov. 08, 2016 -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until January 3, 2017 to file lead plaintiff applications in securities class action lawsuits against Allergan plc (NYSE:AGN), if they purchased the Company’s securities between February 25, 2014 and November 3, 2016, inclusive (the “Class Period”). This action is pending in the United States District Courts for the Central District of California and Southern District of New York.
What You May Do
If you purchased shares of Allergan and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, call toll-free at 1-877-515-1850 or email KSF Managing Partner Lewis Kahn ([email protected]). If you wish to serve as a lead plaintiff in this class action, you must petition the Court by January 3, 2017.
About the Lawsuit
Allergan and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On November 3, 2016, Bloomberg reported that an “antitrust investigation by the Justice Department, begun about two years ago, now spans more than a dozen companies,” including Allergan’s former generic pharmaceuticals unit Actavis, “and about two dozen drugs.” The article further stated that a “grand jury probe is examining whether some executives agreed with one another to raise prices, and the first charges could emerge by the end of the year.” Additionally, according to Bloomberg, “[g]eneric drug companies are also contending with a civil price-fixing investigation by [the] Connecticut Attorney General.”
About Kahn Swick & Foti, LLC
KSF, whose partners include the Former Louisiana Attorney General Charles C. Foti, Jr., is a law firm focused on securities, antitrust and consumer class actions, along with merger & acquisition and breach of fiduciary litigation against publicly traded companies on behalf of shareholders. The firm has offices in New York, California and Louisiana.
To learn more about KSF, you may visit www.ksfcounsel.com.
Contact: Kahn Swick & Foti, LLC Lewis Kahn, Managing Partner [email protected] 1-877-515-1850 206 Covington St. Madisonville, LA 70447
